Development and validation of a bedside nomogram for predicting 30-day mortality in patients with type 1 hepatorenal syndrome: A retrospective cohort study

开发和验证用于预测1型肝肾综合征患者30天死亡率的床旁列线图:一项回顾性队列研究

阅读:1

Abstract

Type 1 hepatorenal syndrome (T1HRS) is the most rapidly progressive form of functional renal failure in decompensated cirrhosis, with 30-day mortality exceeding 50%. We aimed to develop and internally validate a bedside nomogram to predict 30-day death in intensive care unit (ICU) patients with T1HRS. Using the Medical Information Mart for Intensive Care IV database, adults who met diagnostic criteria for T1HRS within 48 hours of ICU admission (2008-2019) were randomly split 7:3 into development (n = 340) and internal validation (n = 146) sets. Predictors collected within 24 hours of diagnosis were selected using least absolute shrinkage and selection operator-Cox; a multivariable Cox model was constructed and internally validated. Performance was assessed by area under the curve, calibration slope, and decision-curve analysis. Overall 30-day mortality was 47.1% (229/486). Seven variables were retained: model for end-stage liver disease-sodium, total bilirubin, international normalized ratio, serum creatinine, mean arterial pressure, urine Na+, and terlipressin use. The model achieved the area under the curves of 0.82 (development) and 0.81 (validation) at 30 days, with a calibration slope of 0.99. The findings were robust to competing-risk, terlipressin exclusion, and Child-Pugh substitution. A 7-variable nomogram provides accurate, well-calibrated, and clinically actionable prediction of 30-day mortality in ICU patients with T1HRS, ready for prospective evaluation and trial stratification.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。